Mahesh Chandrasekhar, MD
Hospitalist · Winston Salem, NCNPI 1033537774
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 80.9% of it on its own, with 25 other manufacturers making up the rest. Among hospitalist clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $344.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$70K
- Heartflow, Inc.$10K
- Abbott$2K
- Boston Scientific$783
- Medtronic$495
- Amgen$364
- plus $2K from 20 others
Across 1 payment — averaging $14,060 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$14K
What the payments were for
- Consulting fees$21,06524%
- Speaking & faculty fees$47,26155%
- Travel & lodging$10,24812%
- Food & beverage$7,4129%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 71 | $69,689 |
| Heartflow, Inc. | 8 | $10,272 |
| Abbott | 20 | $2,193 |
| Boston Scientific | 31 | $783 |
| Medtronic(2 entities) | 5 | $495 |
| Amgen | 22 | $364 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $308 |
| Edwards Lifesciences | 5 | $301 |
| Pfizer | 17 | $298 |
| Abiomed | 3 | $257 |
| Novartis | 12 | $186 |
| Boehringer Ingelheim | 10 | $167 |
| Alnylam Pharmaceuticals Inc. | 6 | $163 |
| AstraZeneca | 5 | $131 |
| Bayer | 7 | $113 |
| Lexicon Pharmaceuticals, Inc. | 3 | $56 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $52 |
| Philips North America LLC | 2 | $45 |
| Merck | 3 | $41 |
| Johnson & Johnson | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Novo Nordisk | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Cvrx, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$57,780
- FFRct$10,264
- MitraClip$1,336
- COREVALVE EVOLUT R$284
- GENERAL - STRUCTURAL HEART$221
- TRICLIP$150
- SAPIEN 3 Ultra RESILIA$133
- LifeVest$118
- PASCAL$115
- Impella$103
How this compares
$86,107 in reported general payments places this provider in the 95th percentile of 879 hospitalist providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 117 | $1,008,488 |
| EliquisApixaban | 256 | $251,990 |
| Repatha SureclickEvolocumab | 145 | $136,267 |
| JardianceEmpagliflozin | 117 | $119,799 |
| EntrestoSacubitril/Valsartan | 88 | $95,388 |
| XareltoRivaroxaban | 54 | $48,950 |
| FarxigaDapagliflozin Propanediol | 50 | $48,818 |
| WegovySemaglutide | 13 | $17,008 |
| Praluent PenAlirocumab | 20 | $16,393 |
| InvokanaCanagliflozin | 26 | $15,648 |
| VascepaIcosapent Ethyl | 21 | $10,770 |
| Ezetimibe | 270 | $4,780 |
| Rosuvastatin Calcium | 327 | $4,012 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 118 | $3,326 |
| Verapamil SrVerapamil Hcl | 14 | $2,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $69,689 | $1,008,488117 claims |
| PfizerEliquis | $298 | $251,990256 claims |
| Boehringer IngelheimJardiance | $167 | $119,799117 claims |
| NovartisEntresto | $186 | $95,38888 claims |
| Johnson & JohnsonXarelto, Invokana | $37 | $64,59780 claims |
| AstraZenecaFarxiga | $131 | $48,81850 claims |
| Novo NordiskWegovy | $30 | $17,00813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 879 hospitalist providers in North Carolina.
Other hospitalist in Winston Salem
- Thomas WolffWinston Salem$8K
- Martin AgbemabieseWinston Salem$8K
- Christopher FortWinston Salem$7K
- Brendan McQuellonWinston Salem$7K
- Kale RothWinston Salem$7K
- Christopher PhillipsWinston Salem$7K
- Jeremy YoungWinston Salem$7K
- Nortei DowuonaWinston Salem$6K
- Vidhya ChandramohanWinston Salem$6K
- Jennifer HausmanWinston Salem$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.